{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:36:08Z","timestamp":1793090168811,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105591","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:04:16Z","timestamp":1788879856000},"page":"105591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The double-edged sword of PD\u20111\/PD\u2011L1 blockade: Bridging hepatocellular carcinoma to liver transplantation while minimizing allograft injury"],"prefix":"10.1016","volume":"227","author":[{"given":"Pooya","family":"Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahd","family":"Alkhazna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stela","family":"Celaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2026.105591_bib1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/cancers15051433","article-title":"Immune checkpoint inhibitors for solid tumors in the adjuvant setting: current progress, future directions, and role in transplant oncology","volume":"15","author":"Abboud","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105591_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PloS. One"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105591_bib4","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/jcm13113068","article-title":"Utilization of immunotherapy as a neoadjuvant therapy for liver transplant recipients with hepatocellular carcinoma","volume":"13","author":"Abdelrahim","year":"2024","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105591_bib5","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers14071760","article-title":"Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view","volume":"14","author":"Abdelrahim","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105591_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001304","article-title":"Immune checkpoint inhibitor therapy before liver transplantation\u2014case and literature review","volume":"8","author":"Aby","year":"2022","journal-title":"Transplant. Direct"},{"key":"10.1016\/j.critrevonc.2026.105591_bib7","article-title":"Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma","author":"Aceituno","year":"2026","journal-title":"Aliment. Pharmacol. & Ther."},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105591_bib8","article-title":"Evaluating the safety of immune checkpoint inhibitors prior to liver transplant","volume":"43","author":"Aceituno","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1159\/000546711","article-title":"Rechallenging Unresectable Hepatocellular Carcinoma with the STRIDE Regimen: A Case Report of Significant AFP Response after Atezolizumab-Bevacizumab Intolerance","volume":"18","author":"Adhikari","year":"2025","journal-title":"Case Rep. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/cancers14010113","article-title":"Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises","volume":"14","author":"Alkharabsheh","year":"2021","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105591_bib11","first-page":"1359","article-title":"T-cell immune monitoring by the ELISPOT assay for interferon gamma","volume":"413","author":"Augustine","year":"2012","journal-title":"Clin. Chim. Acta Peripher. Biomark. a Complement. Tool. TDM Individ. Immunosuppr. Transplant. Med."},{"key":"10.1016\/j.critrevonc.2026.105591_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1371554","article-title":"The value of extracorporeal photopheresis as an immunosuppression-modifying approach in solid organ transplantation: A potential solution to an unmet medical need","volume":"15","author":"Augusto","year":"2024","journal-title":"Front. Immunol."},{"issue":"7_ement","key":"10.1016\/j.critrevonc.2026.105591_bib13","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1158\/1538-7445.AM2026-6303","article-title":"Abstract 6303: Designing an integrative theoretical framework for predicting endocrine toxicity in a large prospective cohort of cancer patients treated with immune checkpoint inhibitor therapy","volume":"86","author":"Awad","year":"2026","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105591_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"New. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib15","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ki.2013.236","article-title":"Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation","volume":"84","author":"Bestard","year":"2013","journal-title":"Kidney Int."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105591_bib16","article-title":"Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)","volume":"S0168-8278","author":"Bhoori","year":"2026","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105591_bib17","article-title":"Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits","volume":"37","author":"Bolufer","year":"2024","journal-title":"Transplant. Int. Off. J. Eur. Soc. Organ. Transplant."},{"key":"10.1016\/j.critrevonc.2026.105591_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1058605","article-title":"Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy","volume":"14","author":"Borch","year":"2023","journal-title":"Front. Genet."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105591_bib19","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I Study of Single-Agent Anti\u2013Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105591_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000548773","article-title":"Evaluating Urinary Biomarkers for Early Detection of Kidney Damage in Immune Checkpoint Inhibitors-Treated Patients","author":"Casanova","year":"2025","journal-title":"Am. J. Nephrol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105591_bib21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105591_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105591_bib23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/life13071562","article-title":"Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution","volume":"13","author":"Cesario","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.critrevonc.2026.105591_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101386","article-title":"Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period","volume":"66","author":"Chen","year":"2021","journal-title":"Transplant. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105591_bib25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/JIR.S495515","article-title":"Predicting Time to First Rejection Episode in Lung Transplant Patients Using a Comprehensive Multi-Indicator Model","volume":"18","author":"Chen","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.critrevonc.2026.105591_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105591_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transplant. Int. Off. J. Eur. Soc. Organ. Transplant."},{"key":"10.1016\/j.critrevonc.2026.105591_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1205997","article-title":"Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy","volume":"14","author":"Chouik","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105591_bib29","article-title":"European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma","volume":"36","author":"Claasen","year":"2023","journal-title":"Transplant. Int. Off. J. Eur. Soc. Organ. Transplant."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105591_bib30","first-page":"946","article-title":"A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma","volume":"24","author":"Court","year":"2018","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105591_bib31","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib32","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/TP.0000000000004108","article-title":"The Impact of Treatment of Hepatocellular Carcinoma With Immune Checkpoint Inhibitors on Pre- and Post-liver Transplant Outcomes","volume":"106","author":"Dave","year":"2022","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105591_bib33","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.ajt.2026.02.010","article-title":"Immune checkpoint inhibitors after liver transplantation: The role of immunosuppressive management","volume":"26","author":"De Martin","year":"2026","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105591_bib34","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib35","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s12328-021-01521-4","article-title":"Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy","volume":"14","author":"Dehghan","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105591_bib36","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.tp.0000250757.69384.79","article-title":"Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival","volume":"82","author":"Dudler","year":"2006","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/gutjnl-2025-336719","article-title":"Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: A multicentre retrospective cohort study","volume":"75","author":"Fang","year":"2026","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib38","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/gutjnl-2025-336719","article-title":"Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: A multicentre retrospective cohort study","volume":"75","author":"Fang","year":"2026","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105591_bib39","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management","volume":"107","author":"Ferr\u00e1ndiz-Pulido","year":"2023","journal-title":"Transplantation"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105591_bib40","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105591_bib41","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105591_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1733357","article-title":"A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition","volume":"16","author":"Flatt","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105591_bib43","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.21037\/atm-20-5207","article-title":"Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction","volume":"9","author":"Florou","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105591_bib44","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/jnci\/djab067","article-title":"Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker","volume":"113","author":"Fountzilas","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105591_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 Pathway in Tolerance and Autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105591_bib46","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.3390\/cancers13246307","article-title":"Liver transplantation for hepatocellular carcinoma after downstaging or bridging therapy with immune checkpoint inhibitors","volume":"13","author":"Gao","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105591_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940473","article-title":"Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?","volume":"12","author":"Gonvers","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105591_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2025.1531852","article-title":"Neoadjuvant therapy for hepatocellular carcinoma-priming precision innovations to transform HCC treatment","volume":"12","author":"Goodsell","year":"2025","journal-title":"Front. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib49","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41416-023-02558-7","article-title":"Soluble lymphocyte activation gene-3 (sLAG3) and CD4\/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies","volume":"130","author":"Gorgulho","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105591_bib50","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment. Pharmacol. & Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105591_bib51","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105591_bib52","first-page":"135","article-title":"Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial","volume":"32","author":"He","year":"2026","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib53","doi-asserted-by":"crossref","first-page":"112","DOI":"10.14740\/wjon1263","article-title":"First Report of Severe Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant in a Patient With Myelodysplastic Syndrome Treated With Atezolizumab: Literature Review","volume":"11","author":"Hsiao","year":"2020","journal-title":"World J. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib54","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib55","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000534303","article-title":"Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?","volume":"13","author":"Hwang","year":"2023","journal-title":"Liver Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14209","article-title":"Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma","volume":"26","author":"Kang","year":"2022","journal-title":"Pediatr. Transplant."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105591_bib57","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.3390\/cancers17233870","article-title":"Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma","volume":"17","author":"Kapelanski-Lamoureux","year":"2025","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105591_bib58","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3390\/cancers14092056","article-title":"Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation","volume":"14","author":"Katariya","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib59","first-page":"8","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis","volume":"43","author":"Kayali","year":"2023","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105591_bib60","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.3390\/cancers16173083","article-title":"Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression","volume":"16","author":"Khaddour","year":"2024","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105591_bib61","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.3390\/jcm14145152","article-title":"Immune Checkpoint Inhibitors and Allograft Rejection Risk: Emerging Evidence Regarding Their Use in Kidney Transplant Recipients","volume":"14","author":"Khan","year":"2025","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105591_bib62","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/cancers16101852","article-title":"Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib63","first-page":"815","article-title":"The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma","volume":"31","author":"Kodali","year":"2025","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105591_bib64","doi-asserted-by":"crossref","first-page":"224","DOI":"10.17998\/jlc.2024.05.12","article-title":"Downstaging with atezolizumab-bevacizumab: A case series","volume":"24","author":"Kulkarni","year":"2024","journal-title":"J. Liver Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105591_bib65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105591_bib66","article-title":"Navigating the risks: A systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes","volume":"15","author":"Liu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105591_bib67","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.2147\/JIR.S546164","article-title":"Establishment and Validation of a Novel Nutritional-Immune-Inflammatory Score Model for Predicting Survival Prognosis in Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors","volume":"18","author":"Liu","year":"2025","journal-title":"J. Inflamm. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105591_bib68","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.14309\/ajg.0000000000001391","article-title":"Immunotherapy as a Downstaging Tool for Liver Transplantation in Hepatocellular Carcinoma","volume":"116","author":"Lizaola-Mayo","year":"2021","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00262-024-03853-9","article-title":"Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation","volume":"74","author":"Lu","year":"2024","journal-title":"Cancer Immunology Immunotherapy CII"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105591_bib70","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1097\/JS9.0000000000001813","article-title":"Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as Neoadjuvant TherapY-PLENTY pilot study","volume":"110","author":"Lv","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105591_bib71","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12916-025-04352-z","article-title":"Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: A global cohort study","volume":"23","author":"Ma","year":"2025","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib72","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/biomedicines12061302","article-title":"Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence","volume":"12","author":"Mart\u00ednez Burgos","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105591_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100003","article-title":"Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN","volume":"1","author":"Mishima","year":"2023","journal-title":"J. Liq. Biopsy"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41525-023-00359-8","article-title":"T-cell priming transcriptomic markers: Implications of immunome heterogeneity for precision immunotherapy","volume":"8","author":"Miyashita","year":"2023","journal-title":"Npj Genom. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105591_bib75","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study","volume":"82","author":"Moeckli","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"Immune checkpoint inhibitors in kidney transplant patients: A multi-center study","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib77","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1111\/ajt.16412","article-title":"Donor plasmacytoid dendritic cells modulate effector and regulatory T cell responses in mouse spontaneous liver transplant tolerance","volume":"21","author":"Nakano","year":"2021","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib78","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib79","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation","volume":"79","author":"Norman","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib80","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.gastha.2023.11.018","article-title":"\u03b1-Fetoprotein, \u03b1-Fetoprotein-L3, and Des-\u03b3-Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk","volume":"3","author":"N\u00fa\u00f1ez","year":"2024","journal-title":"Gastro Hep Adv."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib81","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.21037\/jgo-23-634","article-title":"Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: A case report","volume":"14","author":"Ohm","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2024.101407","article-title":"Rethinking Immune Check Point Inhibitors Use in Liver Transplantation: Implications and Resistance","volume":"19","author":"Ortiz","year":"2025","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105591_bib83","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3390\/cancers17223681","article-title":"Immune Checkpoint Blockade Therapy for Advanced Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients, Transplant Recipients, and Individuals with Hereditary Syndromes: A Narrative Review","volume":"17","author":"Pabianek","year":"2025","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105591_bib84","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/CM9.0000000000003669","article-title":"Immune checkpoint inhibitor-related T-cell-mediated rejection increases the risk of perioperative graft loss after liver transplantation","volume":"138","author":"Pang","year":"2025","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2025.03.001","article-title":"Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: A retrospective cohort study","volume":"9","author":"Pang","year":"2025","journal-title":"Liver Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105591_bib86","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ajt.2026.02.024","article-title":"Expert consensus on the use of immune checkpoint inhibitors in the liver transplant setting: Guidance from the Liver Transplant Committee of the Italian Association for the Study of the Liver (AISF)","volume":"26","author":"Ponziani","year":"2026","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib87","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ni1165","article-title":"Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4","volume":"6","author":"Probst","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105591_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/proteomes10030024","article-title":"Proteomics for Biomarker Discovery for Diagnosis and Prognosis of Kidney Transplantation Rejection","volume":"10","author":"Ramalhete","year":"2022","journal-title":"Proteomes"},{"key":"10.1016\/j.critrevonc.2026.105591_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/gastro\/goag018","article-title":"Liver transplantation for hepatocellular carcinoma: From patient selection and downstaging to risk stratification and post-transplant surveillance","volume":"14","author":"Rezaee-Zavareh","year":"2026","journal-title":"Gastroenterol. Report."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105591_bib92","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"key":"10.1016\/j.critrevonc.2026.105591_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107505","article-title":"Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition","volume":"189","author":"Saal","year":"2024","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105591_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105879","article-title":"Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis","volume":"10","author":"Salani","year":"2025","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2023.0125","article-title":"Recent advances in the management of hepatocellular carcinoma","volume":"30","author":"Sankar","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib96","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/ajt.16965","article-title":"Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab","volume":"22","author":"Schnickel","year":"2022","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105591_bib97","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/hep.31234","article-title":"Immunotherapy as a Downstaging Therapy for Liver Transplantation","volume":"72","author":"Schwacha-Eipper","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib98","first-page":"444","article-title":"Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors","volume":"27","author":"Shi","year":"2021","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib99","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000430","article-title":"Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future","volume":"8","author":"Singal","year":"2024","journal-title":"Hepatol. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105591_bib100","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1097\/TP.0000000000003855","article-title":"Durvalumab as a Successful Downstaging Therapy for Liver Transplantation in Hepatocellular Carcinoma: The Importance of a Washout Period","volume":"105","author":"Sogbe","year":"2021","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JS9.0000000000003520","article-title":"The role of immunotherapy prior to liver transplantation in advanced or down-staged HCC - timing of transplants, selection of patients, and hurdles to overcome with immunosuppression","volume":"112","author":"Tabrizian","year":"2026","journal-title":"Int. J. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105591_bib102","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib103","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105591_bib104","article-title":"Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma","volume":"7","author":"Tabrizian","year":"2025","journal-title":"JHEP Rep. Innov. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib105","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41467-025-67528-4","article-title":"Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: The ReUNION-1 phase 2 trial","volume":"17","author":"Tang","year":"2025","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105591_bib106","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib107","first-page":"444","article-title":"AASLD AST Practice Guideline on adult liver transplantation: Diagnosis and management of graft-related complications","volume":"32","author":"Te","year":"2026","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib108","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.3390\/curroncol30060421","article-title":"The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma","volume":"30","author":"Todeschini","year":"2023","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105591_bib109","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105591_bib110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FTD.0000000000000549","article-title":"Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers","volume":"40","author":"Verhoeven","year":"2018","journal-title":"Ther. Drug. Monit."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105591_bib111","first-page":"598","article-title":"Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss","volume":"29","author":"Wang","year":"2023","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"key":"10.1016\/j.critrevonc.2026.105591_bib112","article-title":"Exhaustion of T cells after renal transplantation","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105591_bib113","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/MNM.0000000000001897","article-title":"Correlation between 18 F-FDG PET\/CT metabolic parameters and microvascular invasion before liver transplantation in patients with hepatocellular carcinoma","volume":"45","author":"Wu","year":"2024","journal-title":"Nucl. Med. Commun."},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2026.105591_bib114","article-title":"Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study","volume":"143","author":"Xu","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105591_bib115","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1039\/D0BM01798A","article-title":"PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation","volume":"9","author":"Yang","year":"2021","journal-title":"Biomater. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105591_bib116","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaccao.2022.07.013","article-title":"Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients","volume":"4","author":"Yeung","year":"2022","journal-title":"Jacc. CardioOncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105591_bib117","first-page":"52","article-title":"Immune checkpoint inhibitors in liver transplant recipients-A review of current literature","volume":"7","author":"Yin","year":"2021","journal-title":"Hepatoma Res."},{"issue":"7830","key":"10.1016\/j.critrevonc.2026.105591_bib118","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41586-020-2631-z","article-title":"Immune-evasive human islet-like organoids ameliorate diabetes","volume":"586","author":"Yoshihara","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105591_bib119","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.transproceed.2025.02.041","article-title":"Successful liver transplantation after achieving complete clinical remission of hepatocellular carcinoma with combination therapy of immune checkpoint inhibitors and targeted agents: a case report","volume":"57","author":"Zhang","year":"2025","journal-title":"Transplant. Proc."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","article-title":"Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Cancer Biol. & Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105591_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2026.101008","article-title":"Diagnostic accuracy of donor-derived cell-free DNA for rejection following liver transplantation: A systematic review and meta-analysis","volume":"40","author":"Zhang","year":"2026","journal-title":"Transplant. Rev."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:52:37Z","timestamp":1793087557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":121,"alternative-id":["S1040842826004786"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105591","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The double-edged sword of PD\u20111\/PD\u2011L1 blockade: Bridging hepatocellular carcinoma to liver transplantation while minimizing allograft injury","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105591"}}